Latest News
PCI Pharma Services Acquires LSNE to Broaden Capabilities in Lyophilisation Manufacturing
Wednesday 13 October 2021

Philadelphia, US-based pharmaceutical and biopharmaceutical integrated solutions provider PCI Pharma Services has signed a definitive agreement to acquire New Hampshire-based contract development and manufacturing organisation Lyophilisation Services of New England, Inc. from private equity firm Permira, the company said.

Terms of the transaction were not disclosed.

Founded in 1997, LSNE serves global pharmaceutical, biotechnology and medical device companies, differentiated by its high-quality cGMP aseptic fill-finish capabilities, and expertise in and ability to scale lyophilisation, an important manufacturing process commonly used with injectable and biologic therapies.

LSNE will expand PCI's breadth of services as a global CDMO, building on PCI's expertise in biologics packaging and speciality manufacturing.

The acquisition adds five FDA-approved facilities in the US (New Hampshire, Wisconsin) and Europe (Spain), with a sixth expecting approval over the coming months, and three additional facilities under development, to strengthen PCI's global 30-site network.

Jefferies LLC acted as exclusive financial advisor and Paul, Weiss, Rifkind, Wharton and Garrison LLP as counsel to PCI Pharma Services.
Date Published: 13/10/2021